All News Alvotech

Equities

ALVO

LU2458332611

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-06-04 pm EDT			5-day change	1st Jan Change
13.95 ^USD	+0.29%		+1.31%	+21.52%

May. 24	Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating	MT
May. 22	Transcript : Alvotech, Q1 2024 Earnings Call, May 22, 2024

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alvotech : Corporate Overview June 2024	Jun. 06	PU
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024	May. 29	GL
Alvotech : Transactions of Managers and Closely Associated Persons	May. 28	PU
Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating	May. 24	MT
Teva and Alvotech Announce SIMLANDI Injection Now Available in the U.S.	May. 22	AQ
Transcript : Alvotech, Q1 2024 Earnings Call, May 22, 2024	May. 22
Alvotech Raises Revenue Guidance for the Full Year 2024	May. 22	CI
Alvotech Narrows Q1 Loss as Revenue Increases; Shares Head Higher Premarket	May. 22	MT
Alvotech Narrows Q1 Loss as Revenue Increases	May. 22	MT
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update	May. 21	GL
Alvotech Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 21	CI
Alvotech Signs Commercialization Deal for Prolia, Xgeva Biosimilar	May. 21	MT
Alvotech and Dr. Reddy's Partner to Commercialize Biosimilar Candidate Denosumab	May. 21	MT
Alvotech : and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK	May. 21	PU
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK	May. 21	GL
Alvotech and Dr. Reddy's Enter into Collaboration for Commercialization of AVT03	May. 21	CI
The latest transactions by star managers	May. 21
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.	May. 20	AQ
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.	May. 20	GL
Teva Pharmaceutical Industries Limited and Alvotech Announce SIMLANDI® Injection Now Available in the U.S	May. 20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Alvotech

Equities

ALVO

LU2458332611

All News

Filters